Introduction {#s1}
============

Doxorubicin (Dox) is one of the most effective chemotherapeutic drugs for the treatment of lung, gastric, ovarian, breast, thyroid, sarcoma, and pediatric cancers ([@B5]; [@B44]; [@B7]). However, long-term use of Dox can produce serious side effects on non-tumor tissues, and thus, its clinical application is limited ([@B36]). There are numerous side effects including hepatotoxicity, nephrotoxicity, and cardiotoxicity, and the toxic effects on the reproductive system and nervous system produced by Dox cannot be reversed ([@B24]; [@B8]; [@B38]; [@B20]; [@B7]; [@B37]; [@B26]). In addition, the metabolites of Dox by hepatic microsomal enzymes and cytoplasmic reductase are adriamycin and hepatotoxic glycosides ([@B4]; [@B9]). As the largest metabolic organ in the body, the liver plays critical roles in metabolism, which can also be easily damaged by Dox. Hence, exploration of active lead compounds against Dox-induced liver damage is necessary.

Drug-induced hepatotoxicity may occur through the formation of free radicals and the production of reactive oxygen species (ROS), which can cause oxidative damage to organs ([@B21]; [@B34]; [@B39]; [@B1]). In addition, the activation of inflammatory response has been found in Dox-induced cardiotoxicity, which can be reduced by suppressing nuclear factor κB (NF-κB) ([@B2]; [@B3]; [@B54]). Some studies have confirmed that Dox-derived ROS can adjust tumor suppressor P53 (P53) signal, release cytochrome *c*, and activate caspase-3 to promote apoptosis ([@B23]; [@B22]; [@B25]). Therefore, simultaneous inhibition of oxidative stress, inflammation, and apoptosis should be one effective method to treat Dox-induced hepatotoxicity.

Silent information regulator 1 (Sirt1), a NAD^+^-dependent class III histone deacetylase, has the ability to deacetylate key metabolic players including peroxisome coactivator 1 alpha, which is also a master regulator of oxidative metabolism and one inducer of oxidative stress protection systems such as manganese superoxide dismutase (SOD) and catalase ([@B6]). Sirt1 can increase cell resistance and survival from stress to protect against Dox-induced oxidative damage and cell death. Overexpression of Sirt1 can protect the heart from oxidative stress through up-regulating the actions of antioxidants ([@B6]; [@B50]). Furthermore, previous studies have demonstrated that Sirt1 can suppress NF-κB and adjust P53 signal, culminating in regulating cardiomyocyte inflammation and apoptosis ([@B12]; [@B50]). Hence, Sirt1 plays critical roles in regulating inflammation, oxidative stress, and apoptosis. However, to the best of our knowledge, there are no mechanistic studies on the roles of Sirt1 in Dox-induced hepatotoxicity.

With the development of modern pharmacology and molecular biology, the potential of natural products and Chinese herbal compounds for the prevention and treatment of human diseases has attracted more and more attention in recent years. Dioscin (shown in [**Figure 1A**](#f1){ref-type="fig"}), a naturally derived triterpenoid saponin, has potent effects against various cancers ([@B30]; [@B40]; [@B57]; [@B14]; [@B42]; [@B47]) and protective activities against organ damage ([@B28]; [@B27];[@B33]; [@B58]; [@B59]; [@B13]; [@B15]; [@B29]), which also has active actions against metabolic diseases including diabetes, hyperuricemia, obesity, and osteoporosis ([@B52]; [@B41]; [@B46]; [@B43]). Actually, beneficial therapeutic effects of dioscin on acute liver injury through alleviation of oxidative stress and suppression of inflammation have been studied, which can also promote liver regeneration ([@B11]; [@B19]; [@B48]; [@B56]; [@B51]; [@B55]; [@B32]). Also, dioscin shows protective effects against Dox-induced nephrotoxicity and cardiotoxicity ([@B16]; [@B31]). Based on these prospective findings, we speculated that dioscin might exert protective effects against Dox-induced hepatotoxicity, and we designed *in vivo* and *in vitro* experiments to verify our hypothesis.

![Dioscin inhibits Dox-induced AML-12 cell damage and liver injury in mice. **(A)** Chemical structure of dioscin. **(B)** Dox-induced nephrotoxicity on AML-12 cell. **(C)** Cytotoxicity of dioscin on AML-12 cells and the effects of dioscin on cell viability induced by Dox. **(D)** Effects of dioscin (50, 100, and 200 ng/ml) for 24-h pretreatment on the cellular morphology and structure of AML-12 cells by bright image (200× magnification) investigation. **(E)** Effects of dioscin on AST and ALT levels in mice. **(F)** H&E staining (200× original magnification) of the liver tissue in mice. All data are expressed as the mean ± SD (*n* = 5 for *in vitro* test and *n* = 8 for *in vivo* test). \**p* \< 0.05, \*\**p* \< 0.01 compared with the model group. ^\#\#^ *p* \< 0.01 compared with the control group. ALT, alanine transaminase; AML-12, alpha mouse liver 12; AST, aspartate transaminase; Dox, doxorubicin; H&E, hematoxylin and eosin.](fphar-10-01030-g001){#f1}

Materials and Methods {#s2}
=====================

Chemicals and Materials {#s2_1}
-----------------------

Dioscin (purity \> 98%) was obtained from *Dioscorea nipponica* Makino ([@B53]), which was dissolved in 0.5% carboxymethyl cellulose sodium (CMC-Na) for *in vivo* experiments and in 0.1% dimethyl sulfoxide (DMSO) for *in vitro* tests. The alanine transaminase (ALT), aspartate transaminase (AST), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), and glutathione peroxidase (GSH-Px) kits were from Nanjing Jiancheng Institute of Biotechnology (Nanjing, China). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was provided by Roche Diagnostics (Basel, Switzerland). The bicinchoninic acid (BCA) protein assay kit, cell lysis buffer, and phenylmethanesulfonyl fluoride (PMSF) were obtained from Beyotime Institute of Biotechnology (Jiangsu, China). Dox and were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Cell Culture {#s2_2}
------------

Alpha mouse liver 12 (AML-12) cells (Shanghai Institute of Biochemistry and Cell Biology, China) were cultured in Dulbecco's modified Eagle medium (DMEM) and Ham's F12 medium with 5 μg/ml of insulin, 5 μg/ml of transferrin, 5 ng/ml of selenium, 40 ng/ml of dexamethasone, and 10% fetal bovine serum, which were maintained in a humidified atmosphere of 5% CO~2~ and 95% O~2~ at 37°C.

Dox-Induced Cell Injury {#s2_3}
-----------------------

Dox was prepared to make a series of working dilutions in serum-free DMEM. The AML-12 cells were plated in 96-well plates at a density of 8 × 10^4^ cells/ml per well for 24 h. Then, the medium was removed, and 100 μL of sample solution with various concentrations of Dox (0, 1, 2, 5, 8, and 10 mM) was added under different treatment times for 24 h. After 10 μL of MTT stock solution (5 mg/ml) was added, the plates were incubated for another 4 h at 37°C, and DMSO (100 ml/well) was added to dissolve formazan crystals. The absorbance was measured with a microplate reader (Thermo, USA) at 490 nm, the results were normalized to control unwanted sources of variation, and the cell morphology was imaged with a phase contrast microscope (Nikon, Japan). Then a suitable concentration of Dox on cell injury was optimized.

Dioscin Toxicity Assay {#s2_4}
----------------------

AML-12 cells were plated in 96-well plates at a density of 8 × 10^4^ cells/ml for 24 h and treated with various concentrations of dioscin (0, 50, 100, 200 400, 800, 1,600, and 3,200 ng/ml) for 6, 12, and 24 h at 37°C, and the cells were then analyzed according to MTT method. The absorbance of the samples was quantified at 490 nm using a phase contrast microscope (Nikon, Japan).

Cell Viability Assay {#s2_5}
--------------------

AML-12 cells were seeded in 96-well plates at a density of 8 × 10^4^ cells/ml for 24 h and then pretreated with various concentrations of dioscin (50, 100, or 200 ng/ml) for 6, 12, and 24 h before being challenged with Dox (5 μg/ml) for 24 h. The cells in the model group were cultured without dioscin pretreatment, and the cells in the control group were cultured in serum-free DMEM under normal conditions during the entire experiment. The MTT assay was used to assess cell viability. The cell morphology was observed by an inverted microscope (Olympus BX-51, Tokyo, Japan).

Measurement of Intracellular ROS Level {#s2_6}
--------------------------------------

AML-12 cells were plated in 6-well culture plates at a density of 8 × 10^4^ cells/ml and treated with dioscin at concentrations of 50, 100, and 200 ng/ml for 12 h before treatment with Dox. The cells were harvested and then re-suspended in 500 ml of DCFH-DA (10 mM) into each well for 20 min at 37°C. After that, the cells were washed three times with serum-free DMEM, and the images were captured by fluorescent microscopy (Olympus, Japan) with 200× magnification.

Dox-Induced Hepatotoxicity *In Vivo* {#s2_7}
------------------------------------

Male C57BL/6J mice weighing 18--22 g were obtained from the Experimental Animal Center of Dalian Medical University (Dalian, China) (SCXK: 2013-0003). All animal experiments were performed according to the guidelines of the Institutional Animal Ethical Committee. Animals were housed in a room under the conditions of constant temperature (22 ± 3°C) and humidity (60%), a 12-h light/dark schedule, and free access to food and water.

After adapting for 1 week, the animals were randomly divided into five groups (*n* = 8): control group, Dox model group, Dio 60 mg/kg + Dox group, Dio 30 mg/kg + Dox group, and Dio 15 mg/kg + Dox group. Dioscin was administered intragastrically at doses of 15, 30, and 60 mg/kg once daily for 14 consecutive days. The mice in the control and model groups were administered with vehicle (0.5% CMC-Na). One hour after dioscin administration on the seventh day, the animals in the model and dioscin-treated groups were injected intraperitoneally with Dox (15 mg/kg) in 0.9% saline (10 ml/kg). After the last dose on the 14th day, the animals were sacrificed, and blood and liver tissues were collected and stored for the test.

Assessment of Biochemical Parameters {#s2_8}
------------------------------------

The serum levels of ALS and AST were measured using the commercial kits according to the manufacturer's instructions. The levels of MDA, SOD, GSH, and GSH-Px in liver tissues were detected according to the manufacturer's instructions.

Histological Examination {#s2_9}
------------------------

The liver tissues were fixed in 10% formalin, embedded in paraffin, and sectioned into 5-mm slices. The slices were stained with hematoxylin and eosin (H&E) and photographed by a light microscope (Nikon Eclipse TE2000-U, Nikon, Japan).

Terminal Deoxynucleotidyl Transferase (TdT)-Mediated dUTP Nick-End Labeling (TUNEL) Assay *In Vivo* and *In Vitro* {#s2_10}
------------------------------------------------------------------------------------------------------------------

Apoptosis detection was executed using the assay kit (Beijing TransGen Biotech Co., Ltd., China) following the manufacturer's instructions. The cells and tissues were treated with or without dioscin before the fluorescein (green)-labeled dUTP solution was added. Finally, the images were captured by a fluorescent microscope (Olympus, Japan) with 200× magnification and analyzed by the Image J software. The experiment was carried out by the researchers blinded to each group of animals.

Immunofluorescence Assay {#s2_11}
------------------------

For the immunofluorescence staining of Sirt1, the formalin-fixed and deparaffinized cells and liver tissue sections of mice were incubated with rabbit anti-Sirt1 in a humidified chamber overnight at 4°C. Then, the fluorescein-labeled secondary antibody followed by DAPI (5 μg/ml) was incubated according to the manufacturer's instructions. TUNEL staining was measured with an *In Situ* Cell Death Detection Kit (TMR Red; Roche, NJ, USA) according to the manufacturer's instructions. The samples were imaged using fluorescence microscopy (Olympus, Japan).

Western Blotting Assay {#s2_12}
----------------------

The total protein samples of liver tissues and cells were extracted using cold lysis buffer containing 1 mM of PMSF based on the manufacturer's protocol, and the protein contents were determined using the BCA Protein Assay Kit. Then the proteins were separated by sodium dodecyl sulfate--polyacrylamide gel electrophoresis (SDS--PAGE) (10--15%), transferred to poly(vinylidene diﬂuoride) (PVDF) membranes (Millipore, USA), blocked, and incubated overnight at 4°C with the primary antibodies listed in [**Table 1**](#T1){ref-type="table"}. After blocking with 5% dried skim milk for 3 h at room temperature, the membranes were incubated with horseradish peroxidase-conjugated antibody at room temperature for 2 h. Finally, the proteins were detected using an enhanced chemiluminescence (ECL) method and imaged by a BioSpectrum Gel Imaging System (UVP, Upland, CA, USA). Finally, the expression levels of the proteins normalized to GAPDH were detected using the ECL method and ChemiDoc XRS (Bio-Rad, USA).

###### 

The information of the antibodies used in the present work.

  Antibody   Source   Dilutions   Company
  ---------- -------- ----------- ---------------------------------
  Sirt1      Rabbit   1:1,000     Proteintech Group, Chicago, USA
  FOXO1      Rabbit   1:1,000     Proteintech Group, Chicago, USA
  NF-κB      Rabbit   1:1,000     Proteintech Group, Chicago, USA
  Keap1      Rabbit   1:1,000     Proteintech Group, Chicago, USA
  Nrf2       Rabbit   1:1,000     Proteintech Group, Chicago, USA
  HO-1       Rabbit   1:1,000     Proteintech Group, Chicago, USA
  P53        Rabbit   1:1,000     Proteintech Group, Chicago, USA
  BAX        Rabbit   1:1,000     Proteintech Group, Chicago, USA
  BCL-2      Rabbit   1:2,000     Proteintech Group, Chicago, USA
  GAPDH      Rabbit   1:2,000     Proteintech Group, Chicago, USA

Quantitative Real-Time Polymerase Chain Reaction (PCR) Assay {#s2_13}
------------------------------------------------------------

The total RNA samples were extracted from the cells and liver tissues using TRIzol reagent (TaKaRa Biotechnology Co., Ltd., China) according to the manufacturer's protocol. Then, the purity of the extracted RNA was determined, and cDNA was synthesized using a PrimeScript^®^ RT reagent kit according to the manufacturer's instructions (TransGen Biotech, Beijing, China). Relative quantitation was performed using the Ct method for recurrent versus primary expression, with GAPDH as an endogenous control, and the fold changes were calculated for each gene. The primers used in the present work are listed in [**Table 2**](#T2){ref-type="table"}.

###### 

The primer sequences used for real-time PCR assay.

  Gene          Forward primer (5′--3′)     Reverse primer (5′--3′)
  ------------- --------------------------- ---------------------------
  Human-GAPDH   GAAAGACAACCAGGCCATCAG       TCATGAATGCATCCTTTTTTGC
  Human-IL-1β   CCCTGAACTCAACTGTGAAATAGCA   CCCAAGTCAAGGGCTTGGAA
  Human-IL-6    ATTGTATGAACAGCGATGATGCAC    CCAGGTAGAAACGGAACTCCAGA
  Human-TNF-α   TCAGTTCCATGGCCCAGAC         GTTGTCTTTGAtGATCCATGCCATT
  Mouse-GAPDH   TGTGTCCGTCGTGGATCTGA        TTGCTGTTGAAGTCGCAGGAG
  Mouse-IL-1β   TCCAGGATGAGGACATGAGCAC      GAACGTCACACACCAGCAGGTTA
  Mouse-IL-6    CCACTTCACAAGTCGGAGGCTTA     CCAGTTTGGTAGCATCCATCATTTC
  Mouse-TNF-α   TATGGCCCAGACCCTCACA         GGAGTAGACAAGGTACAACCCATC

PCR, polymerase chain reaction.

Sirt1 siRNA Transfection Experiment *In Vitro* {#s2_14}
----------------------------------------------

Transfection experiment was performed on AML-12 cells. The Sirt1 siRNA and control siRNA were dissolved in Opti-MEM and then equilibrated for 5 min at room temperature. The cells were transfected with Sirt1 siRNA or non-binding control siRNA using Lipofectamine 2000 reagent according to the manufacturer's protocol. Then, the intracellular ROS level, cell apoptosis, and the protein levels of Sirt1, forkhead box protein O1 (FOXO1), kelch-like ECH-associated protein-1 (keap1), NF-E2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), NF-κB, BCL-2-associated X (BAX), and BCL-2 were measured after 24 h of transfection.

Statistical Analysis {#s2_15}
--------------------

All data were performed with GraphPad Prism 5.0 software (San Diego, CA, USA) and presented as the mean and standard deviation (SD). Statistically significant differences were determined using one-way analysis of variance (ANOVA) followed by the Newman--Keuls test. Comparisons between two groups were performed using an unpaired Student *t*-test. The results were considered to be statistically significant at *p* \< 0.05.

Results {#s3}
=======

Dioscin Rehabilitates Dox-Induced Injury in AML-12 Cells and Mice {#s3_1}
-----------------------------------------------------------------

As shown in [**Figure 1B**](#f1){ref-type="fig"}, the viability of AML-12 cells treated with 5.0 μM of Dox, compared with the control group, for 24 h was decreased at 72.1%, Thus, Dox at the concentration of 5.0 μM was used to treat the cells. As shown in [**Figure 1C**](#f1){ref-type="fig"}, dioscin at the concentrations of 50, 100, and 200 ng/ml significantly protected cells against Dox-induced injury in a dose- and time-dependent manner. Compared with the Dox group, dioscin on 24-h treatment significantly increased the viability of AML-12 cells. Importantly, dioscin at the concentrations of 50, 100, and 200 ng/ml showed no toxicity to the cells. As shown in [**Figure 1D**](#f1){ref-type="fig"}, the morphological changes of the cells including cell shrinkage and structure caused by Dox were all markedly reversed by dioscin. As shown in [**Figure 1E**](#f1){ref-type="fig"}, dioscin significantly reduced the levels of ALT and AST in mice compared with the Dox group. In addition, H&E staining ([**Figure 1F**](#f1){ref-type="fig"}) revealed that the liver in the control group showed normal architecture, and apparent injuries were found in Dox-treated groups, which were all restored by dioscin.

Dioscin Inhibits Dox-Induced Oxidative Stress {#s3_2}
---------------------------------------------

Based on immunofluorescence staining shown in [**Figure 2A**](#f2){ref-type="fig"}, after treatment with dioscin at the concentrations of 100 and 200 ng/ml for 12 h, the ROS levels in cells were significantly decreased than those in the Dox group. As shown in [**Figure 2B**](#f2){ref-type="fig"}, dioscin significantly reduced the level of MDA and increased the levels of GSH, GSH-Px, and SOD in mice compared with the model group.

![Dioscin attenuates oxidative damage in AML-12 cells and mice. **(A)** Effects of dioscin on intracellular ROS level in AML-12 cells treated with Dox. **(B)** Effects of dioscin on MDA, SOD, GSH, and GSH-Px levels in mice. Data are presented as the mean ± SD (*n* = 3 for *in vitro* test and *n* = 8 for *in vivo* test). \**p* \< 0.05 and \*\**p* \< 0.01 compared with the Dox group. ^\#^ *p* \< 0.05, ^\#\#^ *p* \< 0.01 compared with the control group. AML-12, alpha mouse liver 12; Dox, doxorubicin; GSH, glutathione; GSH-Px, glutathione peroxidase; MDA, malondialdehyde; ROS, reactive oxygen species; SOD, superoxide dismutase.](fphar-10-01030-g002){#f2}

Dioscin Attenuates Dox-Induced Apoptosis in AML-12 Cells and Mice {#s3_3}
-----------------------------------------------------------------

As shown in [**Figures 3A, B**](#f3){ref-type="fig"}, more TUNEL-positive cells with green fluorescence were observed in Dox-treated groups than in dioscin-treated groups in AML-12 cells and mice.

![Effects of dioscin on the apoptosis of AML-12 cells and mice using TUNEL assay. **(A)** Dioscin attenuates Dox-induced apoptosis in AML-12 cells. **(B)** Dioscin inhibits Dox-induced liver cell apoptosis in mice. Data are presented as the mean ± SD (*n* = 5 for *in vitro* test and *n* = 8 for *in vivo* test). \**p* \< 0.05 and \*\**p* \< 0.01 compared with the model group. ^\#\#^ *p* \< 0.01 compared with the control group. AML-12, alpha mouse liver 12; Dox, doxorubicin; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling.](fphar-10-01030-g003){#f3}

Dioscin Increases the Levels of Sirt1 in AML-12 Cells and Mice {#s3_4}
--------------------------------------------------------------

As shown in [**Figures 4A, D**](#f4){ref-type="fig"}, the expression levels of Sirt1 in the model groups were markedly decreased than in the control groups *in vivo* and *in vitro*, which were significantly up-regulated by dioscin based on western blotting assay. In addition, the results of immunofluorescence staining ([**Figures 4E, F**](#f4){ref-type="fig"}) confirmed that dioscin markedly increased the expression levels of Sirt1 in AML-12 cells and mice.

![Sirt1 levels are activated in AML-12 cells and mice by dioscin. **(A** *--* **D)** Effects of dioscin on the protein levels of Sirt1 in AML-12 cells and mice. **(E** *--* **F)** Effects of dioscin on the expression levels of Sirt1 based on immunofluorescence staining in AML-12 cells and mice (200× magnification). Data are presented as the mean ± SD (*n* = 3 for *in vitro* test and *n* = 8 for*in vivo* test). \**p* \< 0.05 and \*\**p* \< 0.01 compared with the model group. ^\#^ *p* \< 0.05, ^\#\#^ *p* \< 0.01 compared with the control group. AML-12, alpha mouse liver 12; Sirt1, silent information regulator 1.](fphar-10-01030-g004){#f4}

Dioscin Up-Regulates FOXO1/Keap1/Nrf2 Signal in AML-12 Cells and Mice {#s3_5}
---------------------------------------------------------------------

As shown in [**Figures 5A, B**](#f5){ref-type="fig"}, the protein levels of FOXO1 and Keap1 were significantly decreased, while the protein levels of Nrf2 and HO-1 were increased by dioscin than in the model groups in AML-12 cells and mice.

![Dioscin suppresses the levels of protein in oxidative stress caused by Dox. **(A)** Effects of dioscin on the protein levels of FOXO1, Keap1, Nrf2, and HO-1 in AML-12 cells. **(B)** Effects of dioscin on the protein levels of FOXO1, Keap1, Nrf2, and HO-1 in mice. Data are presented as the mean ± SD (*n* = 3 for *in vitro* test and *n* = 8 for *in vivo* test). \**p* \< 0.05 and \*\**p* \< 0.01 compared with the model group. ^\#^ *p* \< 0.05, ^\#\#^ *p* \< 0.01 compared with the control group. AML-12, alpha mouse liver 12; Dox, doxorubicin; FOXO1, forkhead box protein O1; HO-1, heme oxygenase-1; Keap1, kelch-like ECH-associated protein-1; Nrf2, NF-E2-related factor 2.](fphar-10-01030-g005){#f5}

Dioscin Inhibits Dox-Induced Inflammation in AML-12 Cells and Mice {#s3_6}
------------------------------------------------------------------

As shown in [**Figures 6A--D**](#f6){ref-type="fig"}, the expression levels of NF-κB were significantly decreased by dioscin in AML-12 cells and mice than in the model groups. As shown in [**Figures 6E, F**](#f6){ref-type="fig"}, the mRNA levels of interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) were all significantly decreased by dioscin.

![Dioscin ameliorates inflammation *in vitro* and *in vivo*. **(A** *--* **D)** Effects of dioscin on the expression levels of NF-κB in AML-12 and mice. **(E** *--* **F)** Effects of dioscin on the mRNA levels of IL-1β, IL-6, and TNF-α in AML-12 and mice. Data are presented as the mean ± SD (*n* = 3 for *in vitro* test and *n* = 8 for *in vivo* test). \**p* \< 0.05 and \*\**p* \< 0.01 compared with the model group. ^\#^ *p* \< 0.05, ^\#\#^ *p* \< 0.01 compared with the control group. AML-12, alpha mouse liver 12; IL-1β, interleukin 1β; IL-6, interleukin 6; NF-κB, nuclear factor κB; TNF-α, tumor necrosis factor alpha.](fphar-10-01030-g006){#f6}

Dioscin Affects the Protein Levels Related to Apoptosis in AML-12 Cells and Mice {#s3_7}
--------------------------------------------------------------------------------

As shown in [**Figures 7A--D**](#f7){ref-type="fig"}, the expression levels of tumor suppressor P53 (P53) and BAX were significantly decreased while the expression levels of BCL-2 were increased by dioscin in a dose-dependent manner than in the model groups.

![Dioscin regulates P53-mediated apoptosis pathway *in vivo* and *in vitro*. **(A** *--* **B)** Effects of dioscin on the expression levels of BAX and BCL-2 in AML-12 cells. **(C** *--* **D)** Effects of dioscin on the expression levels of P53, BAX, BCL-2 in mice. All data are presented as the mean ± SD (*n* = 3 for *in vitro* test and *n* = 8 for *in vivo* test). \**p* \< 0.05 and \*\**p* \< 0.01 compared with the model group. ^\#^ *p* \< 0.05, ^\#\#^ *p* \< 0.01 compared with the control group. AML-12, alpha mouse liver 12; BAX, BCL-2-associated X; P53, tumor suppressor P53.](fphar-10-01030-g007){#f7}

Sirt1 siRNA Reverses the Protective Effects of Dioscin on Dox-Induced Cell Injury {#s3_8}
---------------------------------------------------------------------------------

To investigate the roles of Sirt1 on the effects of dioscin against Dox-induced liver damage, a transfection approach using Sirt1 siRNA was carried out. As shown in [**Figure 8A**](#f8){ref-type="fig"}, Sirt1 siRNA weakened the dioscin-induced up-regulation of Sirt1 based on immunofluorescence assay and increased the ROS level and the numbers of TUNEL-positive cells. However, dioscin still up-regulated the expression level of Sirt1, inhibited ROS level, and decreased the numbers of TUNEL-positive cells after transfection. Similar results were also found in the expression levels of the proteins related to oxidative stress, inflammation, and apoptosis in Sirt1 signal ([**Figure 8B**](#f8){ref-type="fig"}). These findings confirmed that dioscin suppressed the signaling of oxidative stress, inflammation, and apoptosis *via* up-regulation Sirt1 signal.

![Sirt1 siRNA reverses the effects of dioscin on Dox-induced cell damage. **(A)** Effects of dioscin on Sirt1 expression, ROS level, and cell apoptosis with or without transfection of Sirt1 siRNA *in vitro*. **(B)** Effects of dioscin on the expression levels of Sirt1, FOXO1, Keap1, Nrf2, HO-1, NF-κB, BAX, and BCL-2 after transfection with Sirt1 in AML-12 cells. Data are presented as the mean ± SD (*n* = 5 for *in vitro* test and *n* = 8 for *in vivo* test). ^\#^ *p* \< 0.05 and ^\#\#^ *p* \< 0.01 versus the Dox group; \**p* \< 0.05 and \*\**p* \< 0.01 versus the Dox group transfected with Sirt1 siRNA. AML-12, alpha mouse liver 12; BAX, BCL-2-associated X; Dox, doxorubicin; FOXO1, forkhead box protein O1; HO-1, heme oxygenase-1; Keap1, kelch-like ECH-associated protein-1; NF-κB, nuclear factor κB; Nrf2, NF-E2-related factor 2; ROS, reactive oxygen species; Sirt1, silent information regulator 1.](fphar-10-01030-g008){#f8}

Discussion {#s4}
==========

Dox, one of the most widely used anticancer drugs, has therapeutic effects on a wide assortment of tumors ([@B35]). However, Dox can cause a range of significant side effects in normal tissues. Hepatotoxicity, a frequent side effect produced by Dox is of particular relevance under situation of preexisting abnormalities on liver function. Several studies have reported the protective effect of antioxidant agents against Dox-induced hepatotoxicity *via* adjustment of inflammation, oxidative stress, and apoptosis ([@B17]; [@B45]). Dioscin, a naturally derived triterpenoid saponin, displayed the activity on fructose-induced renal damage *via* adjustment of Sirt3-mediated oxidative stress, renal fibrosis, lipid metabolism, and inflammation in rats ([@B33]). In addition, dioscin inhibited Dox-induced nephrotoxicity by activating farnesoid X receptor (FXR) to suppress inflammation and oxidative stress, which was proved in NRK-52E cells and rats ([@B32]). In the present paper, dioscin exerted protective effects against Dox-induced damage on AML-12 cells and protected against Dox-induced liver injury in mice *via* suppression of ROS level, decreasing serum levels of ALT and AST and alleviating histopathological changes. These data implied that dioscin had protective effects by inhibiting Dox-induced hepatotoxicity.

The mechanisms responsible for Dox-induced hepatotoxicity are complex. In recent studies, oxidative stress has been considered as one major mechanism of oxidation-induced hepatotoxicity. It is reported that Dox can induce oxidative stress, which is characterized by ROS accumulation and the decrease of antioxidant defense on oxygen imbalance, culminating in attacking and oxidizing DNA and then inducing liver cell apoptosis ([@B45]). In the present study, Dox-induced hepatotoxicity produced oxidative stress as evidenced by the high ROS level in cells; high levels of GSH, GSH-Px, and SOD; and a low level of MDA in mice, which were ameliorated by dioscin. Herein, suppression of oxidative stress may be one potent strategy of dioscin against Dox-induced hepatotoxicity.

Many studies have shown that Sirt1 has critical roles against hepatotoxicity, which is a key player in pro-inflammatory context and oxidative stress during acetaminophen-mediated hepatotoxicity ([@B17]). Sirt1 is also involved in controlling inflammatory responses, which can adjust NF-κB, a key mediator of pro-inflammatory signaling pathway triggered by cytokines. The latest work has confirmed that activating Sirt1/NF-κB pathway can cause the release of pro-inflammatory cytokines in cisplatin-induced nephrotoxicity ([@B18]). In the present work, dioscin exerted anti-inflammatory capability that resulted from the decreased levels of NF-κB, TNF-α, IL-1β, and IL-6 *via* increase of Sirt1 expression level. Therefore, inhibiting inflammatory response through adjusting Sirt1/NF-κB signal may be one powerful strategy of dioscin to treat Dox-induced hepatotoxicity.

FOXO1, one of the isoforms in the FOXO family, plays critical roles in cell proliferation and differentiation ([@B10]). Activating Sirt1 can promote FOXO1 expression and transcription from cytoplasm to nucleus ([@B18]). Moreover, recent studies have shown that resveratrol can reduce Dox-induced cardiomyocytes cell apoptosis through Sirt1-mediated P53 deacetylation, suggesting that Sirt1 activation plays a critical role in apoptosis associated with P53 ([@B49]). The results of this study revealed that dioscin significantly decreased the expression levels of FOXO1, Nrf2, HO-1, P53, and BAX and dramatically up-regulated the expression levels of Keap1 and BCL-2. Taken together, the protective effect of dioscin against Dox-induced liver damage might be attributable to its antioxidative and anti-apoptosis properties through increasing Sirt1 level and activating FOXO1 and P53 pathways. In addition, Sirt1-siRNA transfection tests showed that dioscin showed potent effects against Dox-induced hepatotoxicity *via* regulation of Sirt1/FOXO1/NF-κB signal.

In conclusion, our results indicated that dioscin showed a protective effect against Dox-induced hepatotoxicity through adjusting Sirt1/FOXO1/NF-κB signal ([**Figure 9**](#f9){ref-type="fig"}), which could be developed as a new potential candidate for clinical therapy to treat the disease. However, the deep mechanism of dioscin on Dox-induced hepatotoxicity and its clinical application remains to be further studied

![Diagram of the possible mechanism in which dioscin inhibits Dox-induced hepatotoxicity. Dox inhibits the expression of Sirt1, which could trigger cell oxidative stress, inflammation, and apoptosis *via* Sirt1/FOXO1/NF-κB signal pathway to induce hepatotoxicity. However, dioscin promotes the expression of Sirt1 and inhibits the oxidative stress, inflammation, and apoptosis to rescue Dox-induced hepatotoxicity through the Sirt1/FOXO1/NF-κB signal. Blue color indicates the function of Dox, and red color indicates the function and effect of dioscin. Dox, doxorubicin; FOXO1, forkhead box protein O1; NF-κB, nuclear factor κB; Sirt1, silent information regulator 1.](fphar-10-01030-g009){#f9}
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